Clinical Trial Update: Safety Surveillance of MenACWY-CRM Vaccine in Children

View source ↗

Summary

A completed safety surveillance update for the MenACWY-CRM meningococcal vaccine in children is reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• MenACWY-CRM (Meningococcal conjugate vaccine (serogroups A, C, W, Y) with CRM197)

Snippet

Sponsor: Novartis Vaccines | Conditions: Meningococcal Disease | Status: COMPLETED